Pages that link to "Q44138534"
Jump to navigation
Jump to search
The following pages link to Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. (Q44138534):
Displaying 50 items.
- Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension (Q24598400) (← links)
- Inhaled treprostinil: a therapeutic review (Q24601864) (← links)
- Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease (Q24681558) (← links)
- The limits of oral therapy in pulmonary arterial hypertension management (Q26773209) (← links)
- Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension (Q26775860) (← links)
- The molecular targets of approved treatments for pulmonary arterial hypertension (Q26798308) (← links)
- The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension (Q26992278) (← links)
- Drug treatment of pulmonary hypertension in children (Q26996078) (← links)
- Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course (Q27023074) (← links)
- The genetics of pulmonary arterial hypertension (Q27027507) (← links)
- Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands (Q27342609) (← links)
- Recent progress in understanding pediatric pulmonary hypertension (Q27691453) (← links)
- A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy (Q28072562) (← links)
- Inhalation of Stachybotrys chartarum causes pulmonary arterial hypertension in mice (Q28385412) (← links)
- A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension (Q28513703) (← links)
- Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertension (Q28544778) (← links)
- Bloodstream infections in patients given treatment with intravenous prostanoids (Q30228937) (← links)
- Recent trends in pulmonary arterial hypertension (Q30475192) (← links)
- Right Ventricular Dysfunction and Failure in Chronic Pressure Overload (Q30475529) (← links)
- Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data (Q31108228) (← links)
- Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. (Q33156291) (← links)
- Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial (Q33156379) (← links)
- Pulmonary hypertension: diagnosis and management (Q33157071) (← links)
- Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. (Q33165207) (← links)
- The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension (Q33538017) (← links)
- Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the art (Q33587892) (← links)
- Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. (Q33645081) (← links)
- Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase (Q33782838) (← links)
- Identifying "super responders" in pulmonary arterial hypertension. (Q33788452) (← links)
- Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH). (Q33788506) (← links)
- Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges (Q33788582) (← links)
- Dynamic contrast-enhanced magnetic resonance imaging in patients with pulmonary arterial hypertension (Q33805937) (← links)
- Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery (Q33808635) (← links)
- Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function (Q33806077) (← links)
- Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension (Q33806163) (← links)
- Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics (Q33806168) (← links)
- Transition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up (Q33806206) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases (Q33965825) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension (Q33965859) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension (Q33965898) (← links)
- Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates (Q33965904) (← links)
- Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. (Q34032884) (← links)
- Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report (Q34064492) (← links)
- Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy (Q34088723) (← links)
- Are hemodynamics surrogate end points in pulmonary arterial hypertension? (Q34098418) (← links)
- Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. (Q34197167) (← links)
- Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension (Q34275313) (← links)
- Treating pulmonary arterial hypertension: current treatments and future prospects (Q34318473) (← links)
- Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension. (Q34384302) (← links)
- Inhaled treprostinil and pulmonary arterial hypertension (Q34417507) (← links)